Biomarkers for malignant pleural mesothelioma: Current status

Molecular Diagnosis and Therapy

Volumn 12, Issue 6, 2008, Pages 375-390

  Greillier, Laurent ^a,b,d   Baas, Paul ^c   Welch, John J ^a   Hasan, Baktiar ^a   Passioukov, Alexandre ^a  

^a EORTC DATA CENTER   (Belgium)

^b AIX MARSEILLE UNIVERSITY   (France)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Biomarkers; Cancer; Diagnostics; Mesothelioma; Microarray analysis

Indexed keywords

BIOLOGICAL MARKER; MEGAKARYOTE POTENTIATING FACTOR; MESOTHELIN; OSTEOPONTIN; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; INCIDENCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; KERATINS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PROGNOSIS;

EID: 57349139453     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256303     Document Type: Review

References (138)

1. Bourdes V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 2000 May; 16 (5): 411-7
2. Metintas S, Metintas M, Ucgun I, et al. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002 Dec; 122 (6): 2224-9
3. Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience in 272 cases. Thorax 1997; 52 (11): 507-12
4. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92 (3): 587-93
5. Marinaccio A, Binazzi A, Cauzillo G, et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007 Dec; 43 (18): 2722-8
6. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004 Jan 15; 159 (2): 107-12
7. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999 Feb; 79 (3-4): 666-72
8. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005; 49 Suppl. 1: S3-8
9. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997 Jan; 111 (1): 106-9
10. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993 Jul 15; 72 (2): 389-93
11. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006; 29 (1): 14-9
12. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002; 22 (2): 298-305
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995 Oct; 108 (4): 1122-8
14. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998 Jan; 16 (1): 145-52
15. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998 Mar; 113 (3): 723-31
16. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55 (9): 731-5
17. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005 Jan 1; 23 (1): 184-9
18. Greillier L, Astoul P. Mesothelioma and asbestos related pleural diseases. Respiration 2008; 76 (1): 1-15
19. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 Jul 15; 21 (14): 2636-44
20. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005 Oct 1; 23 (28): 6881-9
21. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 1996 Sep; 224 (3): 288-94; discussion 94-6
22. Maggi G, Casadio C, Cianci R, et al. Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001 Mar; 19 (3): 346-50
23. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006 May; 1 (4): 289-95
24. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007 Jul; 18 (7): 1196-202
25. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007 Jul; 57 (1): 89-95
26. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001 Oct; 22 (5): 485-502
27. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med 1999 Dec; 29 (6): 765-9
28. Dejsomritrutai W, Senawong S, Promkiamon B. Diagnostic utility of CYFRA 21-1 in malignant pleural effusion. Respirology 2001 Sep; 6 (3): 213-6
29. Romero S, Fernandez C, Arriero JM, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996 Jan; 9 (1): 17-23
30. Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001 Jan; 31 (1): 9-16
31. Lai RS, Chen CC, Lee PC, et al. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol 1999 Sep; 29 (9): 421-4
32. Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004 Dec; 126 (6): 1757-63
33. Salama G, Miedouge M, Rouzaud P, et al. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998; 77 (3): 472-6
34. Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005 Aug; 10 (7): 501-7
35. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001 Apr; 119 (4): 1138-42
36. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999 Oct 15; 86 (8): 1488-95
37. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 2000 Jul; 33 (5): 405-10
38. van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2007 Oct 22; 59 (3): 350-4
39. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Diagnostic value of CA 549 in pleural fluid: comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003 Jun; 40 (3): 289-94
40. Pettersson T, Froseth B, Riska H, et al. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988 Nov; 94 (5): 1037-9
41. Atagi S, Ogawara M, Kawahara M, et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 1997 Oct; 27 (5): 293-7
42. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005 Oct 13; 353 (15): 1564-73
43. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007 May 15; 13 (10): 2928-35
44. Beck A, Ivanova A, Ivanov S, et al. Evaluation of plasma osteopontin as early detection and prognosis marker in malignant pleural mesothelioma [abstract no. 11074]. J Clin Oncol 2008 May 20; 26 Suppl. 15
45. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 Apr 3; 287 (13): 1671-9
46. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001 Dec; 7 (12): 4060-6
47. Koguchi Y, Kawakami K, Uezu K, et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003 May 15; 167 (10): 1355-9
48. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004 Jun 15; 10 (12 Pt 1): 3937-42
49. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003 Nov 15; 362 (9396): 1612-6
50. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999 Sep 28; 96 (20): 11531-6
51. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer 2005 Jul; 49 Suppl. 1: S109-11
52. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007 Sep 1; 13 (17): 5076-81
53. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008 Jan; 85 (1): 265-72; discussion 72
54. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006 Jan 15; 12 (2): 447-53
55. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006 May 15; 173 (10): 1155-60
56. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007 Jul; 62 (7): 569-76
57. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006 Sep; 97 (9): 928-32
58. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006 Jul 15; 12 (14 Pt 1): 4225-31
59. Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008 Mar 1; 14 (5): 1431-7
60. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008 Oct; 62 (1): 45-54
61. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008 Aug; 3 (8): 851-7
62. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008 Aug; 61 (2): 235-43
63. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008 Oct 15; 178 (8): 832-7
64. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007 Oct; 132 (4): 1239-46
65. Singhal S, Wiewrodt R, Malden LD, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003 Aug 1; 9 (8): 3080-97
66. Mohr S, Keith G, Galateau-Salle F, et al. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta 2004 Jan 20; 1688 (1): 43-60
67. Rihn BH, Mohr S, McDowell SA, et al. Differential gene expression in mesothelioma. FEBS Lett 2000 Sep 1; 480 (2-3): 95-100
68. Kettunen E, Nissen AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 2001 Feb 15; 91 (4): 492-6
69. Hoang CD, D'Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004 May; 125 (5): 1843-52
70. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002 Sep 1; 62 (17): 4963-7
71. Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006 Sep 1; 12 (17): 5129-35
72. Pass HI, Beck A, Hoshen M, et al. Differential microRNA expression in pleural mesothelioma: implications for early detection and prognostication [abstract no. 11027]. J Clin Oncol 2008 May 20; 26 Suppl.15
73. Benjamin H, Lebanony D, Cohen L, et al. Differential diagnosis of mesothelioma using microRNA assay [abstract no. 22000]. J Clin Oncol 2008 May 20; 26 Suppl.15
74. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999 Jul; 25 (1): 25-32
75. Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003 Jan-Feb; 23 (1B): 531-6
76. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001 Sep 1; 92 (5): 1224-30
77. Foekens JA, Klijn JG, Natoli C, et al. Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen. Int J Cancer 1995 Apr 21; 64 (2): 130-4
78. Zeimet AG, Natoli C, Herold M, et al. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer 1996 Sep 27; 68 (1): 34-8
79. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002 May 1; 62 (9): 2535-9
80. Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19 (7-9): 551-6
81. Strizzi L, Muraro R, Vianale G, et al. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002 Jun; 197 (2): 218-23
82. Filiberti R, Marroni P, Neri M, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005 Sep-Oct; 26 (5): 221-6
83. Betta P, Libener R, Orecchia S, et al. Prognostic serum markers in malignant pleural mesothelioma: epidermal growth factor and platelet-derived growth factor [abstract no. 18097]. J Clin Oncol 2007 Jun 20; 25 Suppl. 18
84. Betta P, Filiberti R, Marroni P, et al. Serum levels of hepatocyte growth factor and epidermal growth factor as prognostic factors in malignant pleural mesothelioma [abstract no. 10080]. J Clin Oncol 2006 Jun 20; 24 Suppl. 18
85. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001 Apr; 193 (4): 468-75
86. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 2004 Aug 16; 91 (4): 771-4
87. Wang J, Lee JJ, Wang L, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004 Sep 15; 10 (18 Pt 1): 6119-25
88. Fischer JR, Ohnmacht U, Rieger N, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006 Oct; 54 (1): 109-16
89. Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R): relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990 Jun; 61 (6): 924-6
90. Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006 Dec; 54 (3): 399-407
91. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 2006 Feb; 51 (2): 207-15
92. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000 Feb 18; 100 (4): 387-90
93. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008 Mar; 33 (3): 502-6
94. Opitz I, Soltermann A, Schramm A, et al. ERCC1: prognostic marker for malignant pleural mesothelioma [abstract no. 235O]. J Thorac Oncol 2008; 3 (4 Suppl. 1): S85
95. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001 Jun; 38 (6): 535-41
96. Bongiovanni M, Cassoni P, De Giuli P, et al. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001 Sep 1; 92 (5): 1245-50
97. Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004 May; 59 (5): 428-33
98. Isik R, Metintas M, Gibbs AR, et al. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 2001 Jul; 95 (7): 588-93
99. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005 May 1; 11 (9): 3303-8
100. López-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006 Mar 15; 66 (6): 2970-9
101. Emri S, Akbulut H, Zorlu F, et al. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer 2001 Aug-Sep; 33 (2-3): 109-14
102. Soini Y, Kinnula V, Kaarteenaho-Wiik R, et al. Apoptosis and expression of apoptosis regulating proteins Bcl-2, Mcl-1, Bcl-X, and Bax in malignant mesothelioma. Clin Cancer Res 1999 Nov; 5 (11): 3508-15
103. O'Kane SL, Pound RJ, Campbell A, et al. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 2006; 45 (4): 449-53
104. Kokturk N, Firat P, Akay H, et al. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005 Nov; 50 (2): 189-98
105. Gordon GJ, Mani M, Mukhopadhyay L, et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007 Mar; 211 (4): 447-54
106. Di Muzio M, Spoletini L, Strizzi L, et al. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Hum Pathol 2000 Nov; 31 (11): 1341-5
107. Kaarteenaho-Wiik R, Soini Y, Pollanen R, et al. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003 Mar; 42 (3): 280-91
108. Edwards JG, McLaren J, Jones JL, et al. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003 May 19; 88 (10): 1553-9
109. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001 Sep 14; 85 (6): 863-8
110. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999 Sep; 81 (1): 54-61
111. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003 Nov; 124 (5): 1916-23
112. Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 2005 Nov; 128 (5): 3382-7
113. Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999 Sep; 189 (1): 72-8
114. Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998 Nov; 186 (3): 300-5
115. Ohta Y, Shridhar V, Kalemkerian GP, et al. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 1999 Jun 15; 85 (12): 2570-6
116. Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002 Jun; 8 (6): 1857-62
117. O'Kane SL, Cawkwell L, Campbell A, et al. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005 Jul; 41 (11): 1645-8
118. Klabatsa A, Sheaff MT, Steele JP, et al. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 2006 Jan; 51 (1): 53-9
119. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003 Apr 16; 95 (8): 598-605
120. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005 Jun 15; 11 (12): 4406-14
121. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004 Feb 1; 10 (3): 849-59
122. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005 Jun; 115 (6): 1503-21
123. Yang X, Sun X. Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers. BMC Bioinformatics 2007; 8: 118
124. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002 Mar; 1 (2): 203-9
125. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003 Jul 31; 22 (31): 4918-23
126. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 Sep 7; 355 (10): 983-91
127. Farrugia DC, Ford HE, Cunningham D, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003 Feb; 9 (2): 792-801
128. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006; 70 (5): 366-77
129. Miyoshi T, Kondo K, Toba H, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur + uracil) in patients with non-small cell lung cancer. Anticancer Res 2007 Jul-Aug; 27 (4C): 2641-8
130. Yu Z, Sun J, Zhen J, et al. Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol 2005 Jul; 20 (3): 871-8
131. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005 Mar 15; 11 (6): 2300-4
132. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007 Jun 10; 25 (17): 2406-13
133. Vogelzang NJ, Herndon JE, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma: a phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997 Jun 1; 79 (11): 2237-42
134. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatine in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998 Apr 15; 82 (8): 1578-84
135. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) [abstract no. 7526]. J Clin Oncol 2007 Jun 20; 25 Suppl. 18
136. Kratzke RA, Wang X, Wong L, et al. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol 2008 Apr; 3 (4): 417-21
137. Chahine B, Grigoriu BD, Conti M, et al. Kinetics of serum soluble mesothelin related peptides and osteopontin in patients with malignant pleural mesothelioma under treatment [abstract no. A864]. Annual Meeting of the American Thoracic Society; 2007 May 18-23; San Francisco (CA)
138. Tajima K, Hirama M, Takagi Y, et al. Serum ERC/mesothelin and plasma osteopontin as markers of chemotherapeutic response in patients with pleural mesothelioma [abstract no. A154]. Annual Meeting of the American Thoracic Society; 2008 May 16-21; Toronto